Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
J Biochem Mol Toxicol ; 32(2)2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29243862

RESUMEN

Sodium benzoate (SB) is a widely used preservative and antimicrobial substance in many foods and soft drinks. However, this compound is generally recognized as safe food additives, but evidence has suggested that a high intake of SB may link to attention deficit-hyperactivity disorder in children. Present study investigate the effects of oral administration of different concentrations of SB (0.56, 1.125, and 2.25 mg/mL) for 4 weeks, on the learning and memory performance tests, and also the levels of malondialdehyde (MDA), reduced glutathione (GSH), and acetylcholinesterase activity (AChE) in the mouse brain. The results showed that SB significantly impaired memory and motor coordination. Moreover, SB decreased reduced GSH and increased the MDA level in the brain significantly (P < 0.001). However, nonsignificant alteration was observed in the AChE activity. These findings suggest that short-term consumption of SB can impair memory performance and increased brain oxidative stress in mice.


Asunto(s)
Conservantes de Alimentos/efectos adversos , Discapacidades para el Aprendizaje/etiología , Trastornos de la Memoria/etiología , Trastornos de la Destreza Motora/etiología , Síndromes de Neurotoxicidad/etiología , Estrés Oxidativo , Benzoato de Sodio/efectos adversos , Acetilcolinesterasa/metabolismo , Animales , Conducta Animal , Encéfalo/enzimología , Encéfalo/metabolismo , Conservantes de Alimentos/administración & dosificación , Glutatión/química , Glutatión/metabolismo , Discapacidades para el Aprendizaje/enzimología , Discapacidades para el Aprendizaje/metabolismo , Peroxidación de Lípido , Masculino , Malondialdehído/metabolismo , Trastornos de la Memoria/enzimología , Trastornos de la Memoria/metabolismo , Ratones , Trastornos de la Destreza Motora/enzimología , Trastornos de la Destreza Motora/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Neuronas/enzimología , Neuronas/metabolismo , Síndromes de Neurotoxicidad/fisiopatología , Oxidación-Reducción , Distribución Aleatoria , Prueba de Desempeño de Rotación con Aceleración Constante , Benzoato de Sodio/administración & dosificación , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo
2.
BMC Neurosci ; 12: 1, 2011 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-21208416

RESUMEN

BACKGROUND: ALPK1 (α-kinase 1) is a member of an unconventional alpha-kinase family, and its biological function remains largely unknown. Here we report the phenotypic characterization of one mutant line, in which the piggyBac (PB) transposon is inserted into the Alpk1 gene. RESULTS: The piggyBac(PB) insertion site in mutants was mapped to the first intron of the Alpk1 gene, resulting in the effective disruption of the intact Alpk1 transcript expression. The transposon-inserted Alpk1 homozygous mutants (Alpk1PB/PB) displayed severe defects in motor coordination in a series of behavioral analysis, including dowel test, hanging wire test, rotarod analysis and footprint analysis. However, the cerebellar architecture, Purkinje cell morphology and electrophysiology of the Purkinje cells appeared normal in mutants. The motor coordination deficits in the Alpk1PB/PB mice were rescued by transgenic mice expressing the full-length Alpk1-coding sequence under the control of the ubiquitous expression promoter. CONCLUSIONS: Our results indicate that ALPK1 plays an important role in the regulation of motor coordination. Alpk1PB/PB mice would be a useful model to provide a clue to the better understanding of the cellular and molecular mechanisms of ALPK1 in the control of fine motor activities.


Asunto(s)
Proteínas Quinasas Dependientes de Calcio-Calmodulina/genética , Cromosomas Artificiales Bacterianos/genética , Elementos Transponibles de ADN/genética , Trastornos de la Destreza Motora/enzimología , Trastornos de la Destreza Motora/genética , Mutagénesis Insercional/métodos , Mutación/genética , Animales , Masculino , Ratones , Ratones Transgénicos , Trastornos de la Destreza Motora/patología
3.
Exp Neurol ; 213(2): 448-55, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18718468

RESUMEN

Edaravone is a free-radical scavenger, an agent being widely used for cerebral ischemia in Japan. To evaluate its efficacy for possible treatment of amyotrophic lateral sclerosis (ALS), we performed a randomized blind trial in ALS model mice. After identification of the clinical onset in each female G93A mutant SOD1 transgenic mouse, we intraperitoneally administered multiple doses of edaravone to the mice and observed their motor symptoms. We also counted the number of lumbar motoneurons, determined the 3-nitrotyrosine/tyrosine ratio, and evaluated the abnormal SOD1 aggregation in the spinal cord at the 10th day after the edaravone injection. Edaravone significantly slowed the motor decline of the transgenic mice. The remaining motoneurons were significantly preserved in the higher-dose edaravone-administered group, and the 3-nitrotyrosine/tyrosine ratios were reduced dose-dependently. Intriguingly, the area of abnormal SOD1 deposition in the spinal cord was significantly decreased in the higher-dose edaravone-administered group. Our results indicate that edaravone was effective to slow symptom progression and motor neuron degeneration in the ALS model mice. These favorable actions might be attributable to the yet unidentified mechanism responsible for reducing the deposition of mutant SOD1.


Asunto(s)
Esclerosis Amiotrófica Lateral/tratamiento farmacológico , Esclerosis Amiotrófica Lateral/enzimología , Antipirina/análogos & derivados , Destreza Motora/efectos de los fármacos , Destreza Motora/fisiología , Superóxido Dismutasa/metabolismo , Animales , Antipirina/administración & dosificación , Edaravona , Femenino , Humanos , Masculino , Ratones , Ratones Transgénicos , Trastornos de la Destreza Motora/tratamiento farmacológico , Trastornos de la Destreza Motora/enzimología , Superóxido Dismutasa/genética , Superóxido Dismutasa-1 , Factores de Tiempo
4.
J Neurochem ; 106(3): 1198-208, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18466336

RESUMEN

Oxidative stress is implicated in the cognitive deterioration associated with normal aging as well as neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. We investigated the effect of ascorbic acid (vitamin C) on oxidative stress, cognition, and motor abilities in mice null for gulono-gamma-lactone oxidase (Gulo). Gulo-/- mice are unable to synthesize ascorbic acid and depend on dietary ascorbic acid for survival. Gulo-/- mice were given supplements that provided them either with ascorbic acid levels equal to- or slightly higher than wild-type mice (Gulo-sufficient), or lower than physiological levels (Gulo-low) that were just enough to prevent scurvy. Ascorbic acid is a major anti-oxidant in mice and any reduction in ascorbic acid level is therefore likely to result in increased oxidative stress. Ascorbic acid levels in the brain and liver were higher in Gulo-sufficient mice than in Gulo-low mice. F(4)-neuroprostanes were elevated in cortex and cerebellum in Gulo-low mice and in the cortex of Gulo-sufficient mice. All Gulo-/- mice were cognitively normal but had a strength and agility deficit that was worse in Gulo-low mice. This suggests that low levels of ascorbic acid and elevated oxidative stress as measured by F(4)-neuroprostanes alone are insufficient to impair memory in the knockouts but may be responsible for the exacerbated motor deficits in Gulo-low mice, and ascorbic acid may have a vital role in maintaining motor abilities.


Asunto(s)
Deficiencia de Ácido Ascórbico/metabolismo , Cognición/fisiología , Trastornos de la Destreza Motora/metabolismo , Estrés Oxidativo/fisiología , Desempeño Psicomotor/fisiología , Animales , Ácido Ascórbico/biosíntesis , Ácido Ascórbico/farmacología , Ácido Ascórbico/uso terapéutico , Deficiencia de Ácido Ascórbico/tratamiento farmacológico , Deficiencia de Ácido Ascórbico/enzimología , Deficiencia de Ácido Ascórbico/genética , Cognición/efectos de los fármacos , Femenino , L-Gulonolactona Oxidasa/deficiencia , L-Gulonolactona Oxidasa/genética , L-Gulonolactona Oxidasa/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Actividad Motora/efectos de los fármacos , Actividad Motora/genética , Actividad Motora/fisiología , Trastornos de la Destreza Motora/tratamiento farmacológico , Trastornos de la Destreza Motora/enzimología , Trastornos de la Destreza Motora/genética , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/genética , Desempeño Psicomotor/efectos de los fármacos
5.
Spine (Phila Pa 1976) ; 32(19): 2070-5, 2007 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-17762807

RESUMEN

STUDY DESIGN: Immunohistochemical and behavioral study using a rat cauda equina compression model. OBJECTIVE: To investigate, after cauda equina compression by spinal canal stenosis (SCS), Rho activation in the spinal cord and cauda equina, and the effect of intrathecal administration of a Rho kinase inhibitor on hypoalgesia and motor dysfunction. SUMMARY OF BACKGROUND DATA: Compression of the cauda equina caused by SCS is a common clinical disorder associated with sensory disturbance and intermittent claudication. Cauda equina compression is thought to reduce blood flow and result in nerve degeneration caused by various cytokines. Rho, a member of the small GTPases, is a signal transmitter. It promotes Wallerian degeneration, decreases blood flow in the spinal cord and brain, and increases expression of several cytokines. Currently, Rho kinase inhibitor is used clinically to treat progressive nerve damage due to cerebrovascular disorders. However, its effect for SCS has not been evaluated. METHODS: Forty-two 6-week-old male Sprague-Dawley rats (200-250 g) were used. For the SCS model (n = 27), a small piece of silicon was placed under the lamina of the fourth lumbar vertebra. In the sham-operated group, laminectomies were performed at L5 only (n = 15). We examined mechanical sensitivity and motor function using von Frey hairs and a treadmill, and immunohistochemically localized Rho in the spinal ventral neurons, axons, and Schwann cells in the cauda equina. We also examined the effects of intrathecally administered Rho kinase inhibitor for hypoalgesia or motor dysfunction caused by SCS. RESULTS: We observed motor dysfunction and hypoalgesia and activated Rho-immunoreactive cells in spinal ventral neuroreported to induce neurite and axonal outgrowth in the spinal cord and brain after nervous system injury. In addition, 1 report showed that Rho kinase was involved in Wallerian degeneration that was rescued by Rho kinase inhibitor. Furthermore, it is thought that Rho is involved in TNF-alpha and interleukin (IL) production in the central nervous system, and the production was inhibited by administering Rho kinase inhibitor in the central nervous system. Regardns, axons, and Schwann cells in the cauda equina. Intrathecal administration of Rho kinase inhibitor improved mechanical hypoalgesia and motor dysfunction caused by SCS. CONCLUSION: Activated Rho may play an important role in nerve damage in the cauda equina in SCS. Rho kinase inhibitor may be a useful tool in determining the pathomechanism of cauda equina syndrome caused by SCS.


Asunto(s)
1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/análogos & derivados , Hipoestesia/tratamiento farmacológico , Péptidos y Proteínas de Señalización Intracelular/antagonistas & inhibidores , Trastornos de la Destreza Motora/tratamiento farmacológico , Fármacos Neuroprotectores/farmacología , Polirradiculopatía/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Estenosis Espinal/complicaciones , 1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/administración & dosificación , 1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/farmacología , 1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/uso terapéutico , Animales , Células del Asta Anterior/efectos de los fármacos , Células del Asta Anterior/enzimología , Axones/efectos de los fármacos , Axones/enzimología , Conducta Animal/efectos de los fármacos , Cauda Equina/efectos de los fármacos , Cauda Equina/enzimología , Modelos Animales de Enfermedad , Hipoestesia/enzimología , Hipoestesia/etiología , Hipoestesia/patología , Inyecciones Espinales , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Vértebras Lumbares , Masculino , Destreza Motora/efectos de los fármacos , Trastornos de la Destreza Motora/enzimología , Trastornos de la Destreza Motora/etiología , Trastornos de la Destreza Motora/patología , Degeneración Nerviosa/tratamiento farmacológico , Degeneración Nerviosa/enzimología , Degeneración Nerviosa/etiología , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/uso terapéutico , Umbral del Dolor/efectos de los fármacos , Polirradiculopatía/enzimología , Polirradiculopatía/etiología , Polirradiculopatía/patología , Inhibidores de Proteínas Quinasas/administración & dosificación , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Serina-Treonina Quinasas/metabolismo , Ratas , Ratas Sprague-Dawley , Proyectos de Investigación , Células de Schwann/efectos de los fármacos , Células de Schwann/enzimología , Estenosis Espinal/tratamiento farmacológico , Estenosis Espinal/enzimología , Estenosis Espinal/patología , Factores de Tiempo , Proteínas de Unión al GTP rho/metabolismo , Quinasas Asociadas a rho
6.
J Neurochem ; 101(3): 829-40, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17266727

RESUMEN

The neuronal protein tyrosine phosphatases encoded by mouse gene Ptprr (PTPBR7, PTP-SL, PTPPBSgamma-42 and PTPPBSgamma-37) have been implicated in mitogen-activated protein (MAP) kinase deactivation on the basis of transfection experiments. To determine their physiological role in vivo, we generated mice that lack all PTPRR isoforms. Ptprr-/- mice were viable and fertile, and not different from wildtype littermates regarding general physiology or explorative behaviour. Highest PTPRR protein levels are in cerebellum Purkinje cells, but no overt effects of PTPRR deficiency on brain morphology, Purkinje cell number or dendritic branching were detected. However, MAP kinase phosphorylation levels were significantly altered in the PTPRR-deficient cerebellum and cerebrum homogenates. Most notably, increased phospho-ERK1/2 immunostaining density was observed in the basal portion and axon hillock of Ptprr-/- Purkinje cells. Concomitantly, Ptprr-/- mice displayed ataxia characterized by defects in fine motor coordination and balance skills. Collectively, these results establish the PTPRR proteins as physiological regulators of MAP kinase signalling cascades in neuronal tissue and demonstrate their involvement in cerebellum motor function.


Asunto(s)
Péptidos y Proteínas de Señalización Intracelular/deficiencia , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Trastornos de la Destreza Motora/enzimología , Trastornos de la Destreza Motora/genética , Proteínas Tirosina Fosfatasas/deficiencia , Animales , Conducta Animal/fisiología , Encéfalo/patología , Conducta Exploratoria/fisiología , Femenino , Regulación Enzimológica de la Expresión Génica/genética , Masculino , Ratones , Ratones Noqueados , Trastornos de la Destreza Motora/patología , Neuronas/metabolismo , Fosforilación , Proteínas Tirosina Fosfatasas Clase 7 Similares a Receptores
7.
J Neurotrauma ; 22(3): 398-406, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15785234

RESUMEN

Traumatic spinal cord injury (SCI) results in widespread neuronal cell death. Recent studies have suggested that activated calpain mediates neuronal cell death in the central nervous system. We conducted a study to determine whether calpain mediates neuronal cell death in the motor neurons of the spinal cord after SCI, and whether postinjury administration of the calpain inhibitors N-acetyl- Leu-Leu-Met-CHO (ALLM) and calpain inhibitor III (CI III) (MDL28170) reduces the motor disturbances in rats with a model of SCI. Adult male Wistar rats were subjected to SCI by application of a 20-g weight impactor probe to the spinal cord at T12 for 20 min. The rats were divided into three groups according to whether they were injected intravenously with 0.05-2.5 mg/kg ALLM, 10 mg/kg CI III, or 0.1% DMSO as a control every 24 h for 1 week after SCI. Calpain was activated in the spinal cord at 8 h, 24 h, and 5 days after SCI, and administration of ALLM inhibited its activation. ALLM, as compared to the DMSO vehicle alone, also significantly reduced the number of motor neurons in spinal-cord lesions that were positively labeled at 24 h after SCI with the terminal deoxynucleotidyl transferase-uridine nucleotide end-labeling (TUNEL) technique. Additionally, both the inclined plane test and footprint analysis showed markedly better motor activity after 4 weeks in rats injected with ALLM or CI III than in rats given vehicle only. These results suggest that activation of calpain plays a critical role in the neuronal cell death that follows SCI, and that calpain inhibitors may have benefit in treating the motor disturbances that follow SCI.


Asunto(s)
Calpaína/antagonistas & inhibidores , Glicoproteínas/farmacología , Trastornos de la Destreza Motora/tratamiento farmacológico , Neuronas/efectos de los fármacos , Traumatismos de la Médula Espinal/tratamiento farmacológico , Animales , Calpaína/metabolismo , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Relación Dosis-Respuesta a Droga , Glicoproteínas/uso terapéutico , Masculino , Trastornos de la Destreza Motora/enzimología , Neuronas/enzimología , Ratas , Ratas Wistar , Traumatismos de la Médula Espinal/enzimología , Vértebras Torácicas
8.
Pharmacol Biochem Behav ; 78(1): 35-45, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15159132

RESUMEN

The present work addresses the role of polyamines in learning and general behavior by subjecting transgenic mice overexpressing polyamine catabolic enzyme, spermidine/spermine N(1)-acetyltransferase (SSAT) and their syngenic littermates to neurobehavioral profiling assessment (SHIRPA) and to radial eight-arm maze. The general health and physiological conditions as well as the entire behavioral battery comprising of 34 parameters were recorded. The eight-arm radial maze (8-RAM) task included an initial acquisition task for 9 days followed by a 2-day retention test after a 2-week break. In addition, blood samples were taken for hormone analysis. Transgenic mice, which showed reduced motor activity, aggression and muscle tone, spent more time in the radial maze during initial acquisition and retention tasks as compared with syngenic mice. Moreover, the learning performance of transgenic females was significantly inferior to syngenic females. Interestingly, the levels of several hormones were significantly altered in SSAT transgenic mice; circulating adrenocorticotropic hormone (ACTH) and corticosterone levels were markedly increased while testosterone and thyroidal hormone levels were decreased. These changes may be related to the dramatic increase in brain putrescine levels in SSAT-overexpressing (SSAT-OE) mice, but it is likewise possible that the behavioral changes and learning impairment are attributable to more peripheral mechanisms (such as alterations in steroid hormone metabolism), which in turn, could be a consequence of the disturbed polyamine homeostasis.


Asunto(s)
Acetiltransferasas/biosíntesis , Regulación Enzimológica de la Expresión Génica/fisiología , Aprendizaje por Laberinto/fisiología , Actividad Motora/fisiología , Trastornos de la Destreza Motora/enzimología , Acetiltransferasas/genética , Animales , Femenino , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos DBA , Ratones Transgénicos , Trastornos de la Destreza Motora/genética
9.
Neuroscience ; 115(1): 55-65, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12401321

RESUMEN

Vincristine, a microtubule-depolymerizing agent, is known to induce neuronal cell damage. Biochemical, histological and behavioral alterations were investigated after intracerebroventricular injection of vincristine in mice. Intracerebroventricular injection of vincristine caused caspase-3-like protease activation followed by nucleosomal release in the cerebellum. Histological examinations showed that vincristine-induced damage was relatively specific to granule cells in the cerebellum, and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling-positive cells were observed among these cells. Chromatin condensation, one of the criteria for apoptosis, was seen on electron microscopy. Behavioral changes, namely head movements, pivoting and backward walking, were observed in parallel with the increase of caspase-3-like protease activity and nucleosomal release. Furthermore, motor function tests (bulb balance test and rotating rod test) showed deficits of motor coordination ability. These observations suggest that intracerebroventricular vincristine causes massive apoptosis of cerebellar granule cells accompanied with caspase-3-like protease activation, leading to motor dysfunction, in this model. These vincristine-treated mice should be a useful in vivo model for examination of neuronal apoptosis, which might be involved in a variety of neurodegenerative diseases.


Asunto(s)
Caspasas/metabolismo , Cerebelo/efectos de los fármacos , Trastornos de la Destreza Motora/inducido químicamente , Neuronas/efectos de los fármacos , Vincristina/toxicidad , Animales , Caspasa 3 , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Cerebelo/enzimología , Cerebelo/patología , Relación Dosis-Respuesta a Droga , Endopeptidasas/metabolismo , Activación Enzimática/efectos de los fármacos , Activación Enzimática/fisiología , Inyecciones Intraventriculares , Masculino , Ratones , Ratones Endogámicos ICR , Trastornos de la Destreza Motora/enzimología , Trastornos de la Destreza Motora/patología , Neuronas/enzimología , Neuronas/patología
10.
Neuroscience ; 114(3): 755-67, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12220576

RESUMEN

Traumatic brain injury (TBI) causes neuronal death and alters the plasticity (e.g. morphology) of surviving neurons. Both of these events contribute to TBI-associated neurological deficits, such as memory dysfunction. Although a majority of current research is directed towards identifying biochemical cascades responsible for cell death, little is known about mechanisms of altered neuronal plasticity following TBI. Extracellular signal-regulated kinases (Erk1 and 2) play a critical role in growth and have been implicated in long-lasting neuronal plasticity and memory storage. The activation of Erk following TBI was investigated utilizing an antibody that specifically binds to dually phosphorylated Erk. Using this antibody, we report that lateral cortical impact injury in rats increases Erk phosphorylation both in the cortex and the hippocampus as early as 10 min post-injury. Double immunostaining experiments using either a neuron-specific or an astroglial-specific marker show that the active Erk is localized almost exclusively in neuronal cells. Furthermore, the increase in phospho-Erk immunoreactivity was initially localized to axons and at later time points was observed to be predominantly in the cell soma. This suggests that Erk redistributed over time and may play a role in retrograde signaling. Administration of inhibitors of the Erk cascade worsened retrograde amnesia, impaired performances in hippocampus- and amygdala-dependent memory tasks, and exacerbated motor deficits following TBI. Furthermore, inhibition of this cascade did not have any overt effects on cell survival, but altered neuronal morphology as detected by a dendritic-specific marker. These findings suggest that the Erk cascade plays an essential role for the maintenance of neuronal function and plasticity following TBI.


Asunto(s)
Lesiones Encefálicas/enzimología , Encéfalo/enzimología , Trastornos del Conocimiento/enzimología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Trastornos de la Destreza Motora/enzimología , Animales , Encéfalo/efectos de los fármacos , Lesiones Encefálicas/complicaciones , Trastornos del Conocimiento/etiología , Inhibidores Enzimáticos/farmacología , Masculino , Trastornos de la Destreza Motora/etiología , Ratas , Ratas Long-Evans
11.
Pflugers Arch ; 440(1): 34-41, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10863995

RESUMEN

The voltage-gated K+ channel Kv3.1 is expressed in skeletal muscle and in GABAergic interneurons in the central nervous system. Hence, the absence of Kv3.1 K+ channels may lead to a phenotype of myogenic or neurogenic origin, or both. Kv3.1-deficient (Kv3.1-/-) 129/Sv mice display altered contractile properties of their skeletal muscles and show poor performance on a rotating rod. In contrast, Kv3.1-/- mice on the (129/Sv x C57BL/6)F1 background display normal muscle properties and perform like wild-type mice. The correlation of poor performance on the rotating rod with altered muscle properties supports the notion that the skeletal muscle dysfunction in Kv3.1-/- 129/Sv mice may be responsible for the impaired motor skills on the rotating rod. Surprisingly, we did not find major differences between wild-type and Kv3.1-/- 129/Sv skeletal muscles in either the resting or action potential, the delayed-rectifier potassium conductance (gK) or the distribution of fast and slow muscle fibers. These findings suggest that the Kv3.1 K+ channel may not play a major role in the intrinsic excitability of skeletal muscle fibers although its absence leads to slower contraction and relaxation and to smaller forces in muscles of 129/Sv Kv3.1-/- mice.


Asunto(s)
Trastornos de la Destreza Motora/genética , Contracción Muscular/genética , Fibras Musculares Esqueléticas/enzimología , Enfermedades Musculares/genética , Neuropéptidos/deficiencia , Canales de Potasio con Entrada de Voltaje , Canales de Potasio/deficiencia , Potenciales de Acción/genética , Animales , Canales de Potasio de Tipo Rectificador Tardío , Femenino , Masculino , Ratones , Ratones Endogámicos , Ratones Noqueados , Trastornos de la Destreza Motora/enzimología , Contracción Muscular/fisiología , Músculo Esquelético/enzimología , Enfermedades Musculares/enzimología , Miosinas/metabolismo , Neuropéptidos/genética , Potasio/metabolismo , Canales de Potasio/genética , Canales de Potasio/metabolismo , Canales de Potasio Shaw
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...